Hyperglycemic Hyperosmolar State

Definition

Hyperglycemic hyperosmolar state (HHS) is an acute hyperglycemic emergency defined clinically by severe hyperglycemia accompanied by hyperosmolarity, with neurologic manifestations ranging from altered mentation to more profound impairment of consciousness. ^[1]D5[2]B3b HHS is distinct from diabetic ketoacidosis (DKA), in which ketoacidosis is the dominant biochemical and clinical process; however, hyperosmolarity and ketoacidosis may coexist, producing an overlap or “mixed” presentation. ^[2]B3b[66]C The distinction is clinically important because hyperosmolarity is associated with neurologic vulnerability and requires attention to osmolality-guided assessment and treatment. ^[1]D5[66]C

The references supplied for this revision do not provide a single universally applicable numeric threshold for plasma glucose, effective osmolality, total serum osmolality, pH, bicarbonate, or ketone concentration. Accordingly, numeric cutoffs should not be inferred from this section alone; classification should be based on the complete biochemical profile and clinical context. ^{[1]D5[2]B3b[66]C}

Classification by biochemical phenotype

1. DKA-predominant emergency: Ketoacidosis is the defining biochemical phenotype, while hyperosmolarity is absent or not sufficiently prominent to classify the episode as HHS. Pediatric hyperglycemic-emergency cohorts have used biochemical criteria to distinguish DKA from other phenotypes. ^[2]B3b

2. HHS-predominant emergency: Hyperosmolarity is the dominant feature of the hyperglycemic emergency, with neurologic manifestations serving as important clinical correlates. HHS may occur with an associated acute illness, including severe infection and sepsis. ^[1]D5[65]C

3. Mixed DKA/HHS presentation: This phenotype combines clinically meaningful hyperosmolarity with ketoacidosis. In a pediatric retrospective cohort, 54 of 411 hyperglycemic emergencies met criteria for a mixed presentation, compared with 333 DKA cases and 3 HHS cases. ^[2]B3b A pediatric case report further illustrates that DKA/HHS overlap can occur in a young child with new-onset type 1 diabetes and may increase neurologic risk and complicate fluid and insulin management. ^[66]C

Because overlap is a recognized phenotype, HHS and DKA should not be treated as mutually exclusive labels when both hyperosmolarity and ketoacidosis are present. ^[2]B3b[66]C

Classification by clinical context

Hyperglycemic emergencies may also be classified according to the setting in which hyperglycemia occurs. A proposed COVID-19-era classification separated hyperglycemia in patients without COVID-19 infection from hyperglycemia in patients with COVID-19 infection. ^[3]D5 Within the non-COVID-19 group, patients with type 2 diabetes were described as tending toward more severe hyperglycemia, whereas patients with type 1 diabetes were described as tending toward more ketoacidosis; the proposed explanations included weight gain, reduced exercise, stress, delayed diagnosis, and pandemic-related disruption. ^[3]D5 These contextual categories describe epidemiologic and clinical circumstances rather than replacing biochemical classification as DKA, HHS, or mixed presentation. ^[2]B3b[3]D5

Precipitant classification should be recorded separately from metabolic phenotype. Reported contexts include infection and sepsis; emphysematous pyelonephritis has been reported with HHS and sepsis in an adult case. ^[65]C In children, new-onset type 1 diabetes is a documented context for DKA/HHS overlap. ^[66]C

Axis nomenclature

For consistent documentation, describe each episode across independent axes:

• Glycemic axis: degree and trajectory of hyperglycemia.
• Osmolality axis: measured or calculated serum osmolality and, when used clinically, effective osmolality; this axis determines whether the episode is hyperosmolar. ^{[1]D5[2]B3b[66]C}
• Ketosis/acidosis axis: presence and severity of ketonemia, ketonuria, metabolic acidosis, and bicarbonate or pH disturbance; this axis determines whether DKA criteria are met. ^[2]B3b[66]C
• Neurologic axis: alertness, altered mental status, and other neurologic manifestations, which are central to the clinical assessment of hyperglycemic emergencies. ^[1]D5[2]B3b
• Context/precipitant axis: diabetes type or new-onset status, infection, sepsis, COVID-19 status, and other relevant triggers. ^{[3]D5[65]C[66]C}

The final diagnostic label should combine these axes—for example, “HHS-predominant hyperglycemic emergency with infection-associated sepsis” or “mixed DKA/HHS presentation in new-onset type 1 diabetes”—rather than relying on a single administrative code. This is particularly important because the pediatric cohort found that associated diagnosis codes did not necessarily correspond accurately to biochemical classification. ^[2]B3b

Core endocrine disturbance

Hyperglycemic hyperosmolar state (HHS) develops when effective insulin action is insufficient to restrain hepatic glucose production and peripheral hyperglycemia, while residual endogenous insulin activity is often sufficient to suppress extensive adipose lipolysis and ketogenesis. Counter-regulatory hormones—including glucagon, catecholamines, cortisol, and growth hormone—promote glycogenolysis, gluconeogenesis, insulin resistance, and progressive hyperglycemia. ^{[4]A1c[5]D5[7]D5[8]D5[34]D5} HHS and diabetic ketoacidosis (DKA) therefore share a hormonal substrate, but the balance between insulin deficiency and counter-regulatory activation generally produces more profound hyperglycemia and hyperosmolarity, with less prominent ketoacidosis, in HHS. ^{[4]A1c[7]D5[8]D5[34]D5}

The initiating disturbance may be absolute or relative reduction in effective insulin concentration, increased counter-regulatory hormone activity, impaired access to water, or a combination of these processes. ^{[4]A1c[7]D5[8]D5[34]D5} Severe hyperglycemia increases filtered glucose delivery to the kidney; glucosuria causes osmotic diuresis, with large losses of water and electrolytes. ^{[4]A1c[5]D5[7]D5[8]D5} Progressive volume depletion reduces renal perfusion and limits glucose clearance, thereby worsening hyperglycemia and serum osmolality in a self-reinforcing cycle. ^{[4]A1c[5]D5[7]D5[8]D5}

Biochemical signature

The defining biochemical phenotype is marked hyperglycemia, increased effective serum osmolality, and dehydration, usually with absent or only modest ketoacidosis. Current adult consensus criteria characterize HHS using plasma glucose ≥600 mg/dL (33.3 mmol/L) and effective serum osmolality >300 mOsm/kg or total serum osmolality >320 mOsm/kg, together with limited ketonemia and the absence of substantial acidosis. ^[4]A1c Typical acid–base findings are arterial or venous pH ≥7.30 and serum bicarbonate ≥18 mmol/L, with β-hydroxybutyrate <3.0 mmol/L or only low-grade ketonuria; mixed HHS/DKA presentations can occur when insulin deficiency is more severe. ^[4]A1c

Hyperosmolarity reflects the accumulation of effective extracellular osmoles, principally glucose and sodium-related solute. ^{[4]A1c[5]D5[7]D5[8]D5} Water shifts from the intracellular to extracellular compartment initially buffer extracellular volume loss, but continued osmotic diuresis produces total-body water depletion, intracellular dehydration, and neurological dysfunction. ^{[4]A1c[7]D5[8]D5} Neurological manifestations range from altered mentation to coma and are linked particularly to the severity and rate of increase of osmolality, although the clinical presentation is also shaped by age, comorbidity, and precipitating illness. ^{[4]A1c[7]D5[48]D}

Total-body potassium is commonly depleted through osmotic diuresis, even when the initial serum potassium is normal or elevated because insulin deficiency, hyperosmolality, and extracellular shifts move potassium out of cells. ^{[4]A1c[5]D5[7]D5[8]D5} Sodium concentration may be lowered by glucose-associated water shifts and may rise as water loss becomes dominant; interpretation therefore requires concurrent assessment of glucose, measured sodium, and calculated or measured osmolality. ^{[4]A1c[5]D5[8]D5}

Precipitants and secondary hormonal pathways

Infection, newly recognized diabetes, interruption or inadequate administration of glucose-lowering therapy, acute cardiovascular or cerebrovascular illness, and other physiological stressors can increase counter-regulatory hormones and precipitate HHS. ^{[4]A1c[7]D5[8]D5[34]D5[48]D} Older age and coexisting illness contribute to the historically higher mortality of HHS compared with DKA; an earlier review reported mortality around 15% for HHS, whereas contemporary consensus emphasizes that outcomes depend substantially on timely recognition, comorbidity, and treatment. ^{[4]A1c[7]D5[34]D5}

Catecholamine excess provides a specific secondary pathway to HHS. In pheochromocytoma and paraganglioma, adrenaline and noradrenaline stimulate insulin resistance, aerobic glycolysis, lipolysis, gluconeogenesis, and glycogenolysis, both directly through adrenergic receptors and indirectly through increased glucagon secretion; impaired insulin secretion may further intensify hyperglycemia. ^[47]D Secretory pheochromocytoma or paraganglioma can therefore produce diabetes ranging from mild insulin resistance to profound insulin-deficient states, including HHS and DKA. ^[47]D

Drug-related disruption of glucose homeostasis is also documented. Teprotumumab, an insulin-like growth factor 1 receptor blocker, was associated with hyperglycemia in 5%–12% of trial participants, and a reported patient with prediabetes developed HHS after the first infusion, with glucose 939 mg/dL and preserved bicarbonate of 28 mEq/L, illustrating severe hyperglycemia without the biochemical pattern of marked metabolic acidosis. ^[49]C Ceritinib-associated hyperglycemia can likewise progress to HHS; recurrence after re-administration supports a reproducible drug-related association, although the precise mechanism remains uncertain. ^[50]C

Organ effects and clinical correlates

Hyperosmolarity-induced cellular dehydration may affect the myocardium as well as the brain. A reported HHS case complicated by Takotsubo cardiomyopathy proposed myocardial dehydration with a consequent increase in intracellular calcium as a mechanism for cardiac dysfunction and electrical alternans. ^[51]C Pediatric HHS follows the same broad metabolic principles but requires particular attention to neurological complications, cerebral edema, precipitating factors, and age-specific interpretation of biochemical abnormalities. ^[48]D

Insulin-axis abnormalities can also produce the opposite glycemic phenotype and should not be confused with HHS. A 2024 report described a novel maternally inherited HNF1A variant associated with neonatal hyperinsulinemic hypoglycemia and marked hypersensitivity to diazoxide; conventional diazoxide dosing caused hyperglycemia, highlighting the variability of genetically determined insulin secretion and drug response rather than establishing an HHS mechanism. ^[6]C4

Overview and diagnostic context

Hyperglycemic hyperosmolar state (HHS) is a life-threatening acute complication of diabetes characterized by profound hyperglycemia and hyperosmolality, usually with absent or only limited ketoacidosis. Contemporary consensus criteria identify plasma glucose ≥600 mg/dL (≥33.3 mmol/L) and effective serum osmolality >300 mOsm/kg or total serum osmolality >320 mOsm/kg as key biochemical features; substantial ketoacidosis is not required, and overlap with diabetic ketoacidosis (DKA) is common ^[4]A1c. HHS is therefore a biochemical and clinical spectrum rather than a uniformly distinct syndrome. Mixed DKA–HHS presentations are documented in adults and children, and isolated HHS may be underrecognized when diagnostic coding or initial clinical classification relies on DKA labels ^{[2]B3b[19]C4[53]}.

Epidemiology

HHS occurs in both type 1 and type 2 diabetes but is especially associated with type 2 diabetes, older age, obesity, and progressive insulin deficiency. In a U.S. national analysis of adults with diabetes, emergency-department visits and inpatient admissions for both DKA and HHS were evaluated over 2006–2015, demonstrating the continuing population burden of hyperglycemic crises ^[14]B2c. The available evidence also indicates clinically important recurrence: among adults hospitalized for hyperglycemia, 4.0% were readmitted for recurrent hyperglycemia within 30 days ^[55].

HHS is less frequent than DKA in pediatric cohorts, although its occurrence is increasing in parallel with pediatric obesity and type 2 diabetes. In a pediatric cohort of 411 hyperglycemic emergencies, 3 cases were isolated HHS and 54 had mixed DKA–HHS features; altered mental status was more frequent in hyperosmolar presentations ^[2]B3b. A series of nine Korean adolescents with obesity and type 2 diabetes found that nearly all had overlapping HHS and DKA characteristics, illustrating the diagnostic difficulty of pediatric disease ^[19]C4. In a larger pediatric study, only 31 of 4,565 admissions had isolated HHS, whereas 250 had hyperosmolar DKA, reinforcing that mixed phenotypes substantially outnumber strictly isolated HHS in some settings ^[11]B3b.

Etiology and precipitating conditions

HHS generally reflects inadequate effective insulin action combined with severe dehydration and impaired free-water replacement. The 2024 international consensus report identifies acute illness, treatment-related factors, and interruption or insufficiency of diabetes therapy as major contexts in which hyperglycemic crises develop ^[4]A1c. HHS may also be associated with marked hypernatremia: in a 2018–2024 adult series, measured sodium >145 mmol/L occurred in 8% (14/174) of patients with HHS, supporting recognition of a hyperglycemic hypernatremic or hypertonic subtype ^[10]B3b.

Intercurrent infection and systemic inflammation can precipitate hyperglycemic crises. In adults with type 2 diabetes and COVID-19, inflammatory biomarkers were investigated as predictors of DKA and/or HHS, supporting COVID-19 infection as a clinically relevant trigger ^[54]C. Chronic pancreatitis is another potential contributor; a nationwide cohort specifically evaluated whether chronic pancreatitis increases the risk of DKA or HHS among patients with diabetes ^[9]B2b. Medication-related dysglycemia is also important. A systematic review of clinical case evidence evaluated both first- and second-generation antipsychotics in relation to DKA and HHS, reflecting concern that antipsychotic exposure can contribute to severe hyperglycemic complications ^[18]B3a.

HHS can produce prominent neurological manifestations. Nonketotic hyperglycemic hyperosmolar state has been associated with seizures and a characteristic diffuse subcortical white-matter MRI abnormality termed “dark white matter”; systematic evidence found seizures in more than 60% of previously reported cases with this imaging sign and identified nonketotic HHS as a particularly predictive underlying etiology ^[17]B3a. Acute stroke-like deficits are also reported: in a systematic review of 18 non-epileptic cases, hemianopia was the most common presentation (73%), followed by partial or total anterior-circulation syndromes (26%) ^[16]B3a. These neurological presentations may mimic stroke or seizure-related disease and can delay recognition of HHS ^{[16]B3a[17]B3a}.

Patient-level and health-system risk factors

Risk is increased by kidney failure, multimorbidity, socioeconomic disadvantage, and treatment complexity. In a U.S. Renal Data System study of 521,789 adults with diabetes and end-stage kidney disease, rates of severe hypoglycemic and hyperglycemic crises were examined according to age, sex, race or ethnicity, dialysis modality, comorbidities, treatment regimen, and geographic region ^[13]B2b. Area-level socioeconomic deprivation was independently investigated as a determinant of emergency visits or hospitalizations for DKA or HHS, emphasizing that social conditions influence access to medications, monitoring, nutrition, and timely care ^[52].

A U.S. cohort study also evaluated sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises in adults with type 1 or type 2 diabetes from 2014–2020 ^[38]B3b. Recurrent admission risk is particularly relevant in patients with multiple comorbidities and potentially modifiable treatment or follow-up barriers ^[55][57]. Conversely, population implementation of intermittently scanned continuous glucose monitoring has been evaluated for its effects on hospitalizations and healthcare costs in insulin-treated type 2 diabetes, highlighting glucose monitoring technology as a potential prevention strategy ^[15]B2b.

Overview

Hyperglycemic hyperosmolar state (HHS) is an acute, potentially fatal complication of diabetes characterized by profound hyperglycemia, hyperosmolality, severe water depletion, and comparatively limited ketoacidosis. It most often occurs in people with type 2 diabetes, particularly older adults, but it can occur in children, adolescents, and people with type 1 diabetes. ^{[4]A1c[7]D5[59]D} HHS may be the first recognized manifestation of diabetes; in a registry of youth with type 2 diabetes, 2% presented with HHS at diagnosis, whereas 11% presented with diabetic ketoacidosis (DKA). ^[37]B2b

Biochemical and hydration features

The contemporary adult diagnostic profile generally includes plasma glucose ≥600 mg/dL (≥33.3 mmol/L), effective serum osmolality >300 mOsm/kg or total serum osmolality >320 mOsm/kg, absent or mild ketonemia, and no substantial acidosis, typically with β-hydroxybutyrate <3.0 mmol/L, pH ≥7.30, and bicarbonate ≥15 mmol/L. ^[4]A1c HHS represents a spectrum rather than a completely separate disorder: mixed DKA-HHS presentations are common, and the presence of hyperosmolality does not exclude clinically important ketosis or acidosis. ^[4]A1c[53]

Marked osmotic diuresis produces substantial losses of water and monovalent cations, including sodium and potassium. ^[58]D Patients therefore commonly present with intense thirst, polyuria, generalized weakness, orthostatic symptoms, tachycardia, hypotension, dry mucous membranes, reduced skin turgor, and other signs of severe dehydration. ^{[4]A1c[7]D5[59]D} Renal hypoperfusion may contribute to azotemia and acute kidney injury, while electrolyte abnormalities can produce weakness, arrhythmia, or other systemic manifestations. ^{[4]A1c[7]D5[58]D}

Neurologic manifestations

Neurologic abnormalities are central to the presentation of HHS and range from lethargy, confusion, and drowsiness to stupor and coma. ^{[1]D5[4]A1c[7]D5} The severity of altered mental status generally increases with rising osmolality, although neurologic findings may be variable and may not correlate perfectly with a single laboratory value. ^[1]D5[4]A1c

HHS can produce focal or stroke-like neurologic deficits, including hemianopia, aphasia, hemiparesis, hemisensory loss, dysarthria, and neglect. ^[16]B3a In a systematic review of 18 reported cases of non-epileptic acute neurologic deficits associated with nonketotic HHS, hemianopia was the most frequent manifestation (73%), while partial or complete anterior-circulation syndromes occurred in 26%. ^[16]B3a Patients presenting with an anterior-circulation syndrome were older than those with other stroke-like presentations, with mean ages of 69.5 ± 5.1 years and 52.2 ± 13.9 years, respectively. ^[16]B3a These findings emphasize that focal deficits in HHS may mimic acute ischemic stroke and require urgent neurologic assessment while metabolic abnormalities are corrected. ^[1]D5[16]B3a

Gastrointestinal, infectious, and precipitating features

Clinical presentation may include nausea, vomiting, abdominal discomfort, anorexia, malaise, fever, and symptoms related to the precipitating illness. ^{[4]A1c[7]D5[59]D} Infection is a frequent context, and clinicians should actively search for urinary, pulmonary, gastrointestinal, skin, and other infections. ^[4]A1c[7]D5 Reported cases illustrate the range of infectious presentations: a diabetic patient with HHS had intermittent fever and abdominal discomfort associated with a pyogenic liver abscess, while another presented with progressive abdominal pain, acute renal failure, and bilateral emphysematous pyelonephritis. ^[22]C4[23]C4 Emphysematous urinary infection may therefore present as an apparent hyperglycemic emergency with severe systemic and renal manifestations. ^[22]C4[61]

Medication-related hyperglycemia is another important clinical context. Antipsychotic drugs, particularly second-generation agents, have been associated in clinical reports with severe hyperglycemic complications, including HHS and DKA; evidence involving first-generation agents is less established. ^[18]B3a Other acute illnesses, reduced oral intake, inadequate access to insulin or fluids, and previously undiagnosed diabetes may also contribute to presentation. ^{[4]A1c[7]D5[59]D}

Pediatric and adolescent presentation

Pediatric HHS is uncommon but potentially life-threatening. ^{[2]B3b[19]C4[42]C4[43]C4} Children and adolescents may present with several days of polyuria, polydipsia, vomiting, weakness, altered consciousness, dehydration, hypotension, or tachypnea. ^{[19]C4[42]C4[43]C4} Pediatric cases frequently have overlapping HHS and DKA features, making initial classification difficult. In a cohort of nine obese adolescents with type 2 diabetes and HHS, almost all had both hyperosmolality and ketoacidosis, and 5 of 9 were initially diagnosed with DKA. ^[19]C4 In a pediatric cohort of 411 hyperglycemic emergencies, there were 333 DKA cases, 54 mixed DKA-HHS cases, and only 3 isolated HHS cases; altered mental status was more frequent in hyperosmolar presentations than in uncomplicated DKA. ^[2]B3b

Extreme presentations have been reported, including a 7-year-old with vomiting, polydipsia, polyuria, severe dehydration, and glucose 115 mmol/L, and a 15-year-old with obtundation, hypotension, tachypnea, glucose 90.9 mmol/L, serum osmolality 454 mOsm/kg, and corrected sodium 165 mEq/L. ^[42]C4[43]C4 These cases demonstrate that pediatric HHS may present with both neurologic compromise and severe circulatory depletion, and that very high glucose does not reliably distinguish isolated HHS from mixed DKA-HHS. ^{[2]B3b[19]C4[42]C4[43]C4}

Important diagnostic considerations

Persistent hypernatremia or unexpectedly dilute urine after apparent correction of HHS should prompt consideration of an additional water-balance disorder. A reported patient developed persistent hypernatremia without thirst after HHS; central diabetes insipidus became evident later, with polydipsia reaching 10 L/day, and was confirmed after dapagliflozin was discontinued for 48 hours. ^[21]C4 Thus, ongoing polyuria, hypernatremia, or failure of serum osmolality to improve should not automatically be attributed to unresolved HHS. ^[4]A1c[21]C4

HHS should be suspected in any patient with severe hyperglycemia, dehydration, and neurologic change, even when focal deficits, infection, abdominal symptoms, or apparent DKA dominate the initial presentation. ^{[1]D5[4]A1c[16]B3a[19]C4}

Diagnostic principle

Hyperglycemic hyperosmolar state (HHS) is a clinical and biochemical emergency defined by severe hyperglycemia, marked hyperosmolality, dehydration, and variable neurologic dysfunction; it is not diagnosed by a paired-hormone profile, endocrine stimulation test, or an anatomic localization study.^[4]A1c[25]D5 The key diagnostic task is to confirm hyperosmolar hyperglycemia promptly, determine whether diabetic ketoacidosis (DKA) coexists, identify the precipitating illness or medication, and assess neurologic complications.^[4]A1c[25]D5

The 2024 international consensus report recommends assessing plasma glucose, electrolytes, venous or arterial blood gas, serum or capillary β-hydroxybutyrate when available, renal function, and serum osmolality in suspected HHS.^[4]A1c HHS is conventionally characterized by glucose ≥600 mg/dL (33.3 mmol/L) and effective serum osmolality >300 mOsm/kg or total serum osmolality >320 mOsm/kg, with little or no clinically significant ketoacidosis.^[4]A1c[25]D5 Effective osmolality is calculated from sodium and glucose and better reflects the tonicity responsible for neurologic manifestations, whereas total osmolality includes urea.^[4]A1c[28]D5 Because definitions and reporting have historically differed between the United States and United Kingdom, the laboratory values and formula used should be documented explicitly.^[28]D5

Paired hormones and dynamic testing

Routine paired measurements of insulin, C-peptide, cortisol, growth hormone, thyroid hormones, or other endocrine hormones do not establish HHS and should not delay emergency treatment.^[4]A1c[25]D5 HHS generally reflects relative insulin deficiency accompanied by counterregulatory hormonal activation, but the diagnosis rests on glucose, osmolality, acid-base status, ketones, and clinical findings rather than on dynamic endocrine testing.^[25]D5

Hormonal testing is appropriate only when the presentation suggests a separate endocrine disorder that could precipitate or mimic hyperglycemic crisis. For example, thyroid testing may be clinically indicated when there are features of thyroid storm or myxedema coma, and cortisol evaluation may be considered when adrenal crisis is suspected; these are differential-diagnosis investigations rather than HHS confirmation tests.^[1]D5 Medication and exposure review is essential because antipsychotic drugs, particularly second-generation agents, have been associated in clinical reports with DKA and HHS.^[18]B3a SGLT2-inhibitor use should also be recorded, particularly when persistent hypernatremia, polyuria, or unexpectedly dilute urine raises concern for coexisting central diabetes insipidus after HHS.^[21]C4

Initial biochemical workup

Obtain serum sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, and calculated or measured osmolality, together with venous pH and ketones.^[4]A1c[25]D5 Calculate the anion gap when assessing for mixed DKA-HHS, but interpret it with the direct ketone measurement and acid-base results because HHS and DKA frequently overlap.^[4]A1c[25]D5 A mixed presentation should be considered when substantial ketonemia, metabolic acidosis, or bicarbonate reduction accompanies hyperosmolality; pediatric series demonstrate that such overlap is common and may lead to initial misclassification as DKA or HHS.^[2]B3b[19]C4

Measure sodium directly and calculate a glucose-corrected sodium when evaluating the water deficit, because marked hyperglycemia can mask the degree of underlying hypernatremia.^{[4]A1c[10]B3b} Hypernatremic HHS is clinically important: in a 2018–2024 adult cohort, measured sodium above 145 mmol/L occurred in 8% of patients, although corrected sodium and the calculated water deficit identified a broader subgroup with clinically relevant free-water loss.^[10]B3b Persistent or disproportionate hypernatremia should prompt review of urine volume, urine specific gravity, and urine osmolality, while recognizing that dapagliflozin can obscure the interpretation of urine concentration until it is discontinued.^[21]C4

Neurologic assessment and localization

Document mental status, seizures, focal deficits, visual symptoms, and evidence of cerebral injury at presentation and during treatment.^[4]A1c[1]D5 Altered consciousness can result from hypertonicity itself, but seizures or focal findings require evaluation for stroke, infection, toxic-metabolic disease, or a peri-ictal imaging abnormality.^[1]D5[4]A1c

Brain CT or MRI is not required to diagnose uncomplicated HHS, but neuroimaging is indicated for unexplained focal deficits, persistent coma, recurrent seizures, severe headache, trauma, or failure of neurologic recovery as osmolality improves.^[1]D5[4]A1c Diffuse subcortical T2/FLAIR hypointensity, termed dark white matter, has been reported particularly in nonketotic hyperglycemic hyperosmolar states associated with seizures.^[17]B3a A systematic review found that more than 60% of published dark-white-matter cases were associated with seizures, and cortical or subcortical abnormalities may also suggest alternative inflammatory etiologies such as anti-MOG encephalitis.^[17]B3a MRI findings therefore support etiologic and neurologic localization but do not replace biochemical confirmation of HHS.^[17]B3a

Search for precipitants and mimics

Investigate infection, myocardial ischemia, stroke, medication exposure, missed insulin or other diabetes therapy, and newly recognized diabetes according to the clinical presentation.^[4]A1c[25]D5 Urinalysis, cultures, chest imaging, electrocardiography, cardiac biomarkers, and targeted imaging should be obtained when clinically indicated rather than indiscriminately.^[4]A1c[63]D Severe infection may be occult; emphysematous pyelonephritis, for example, has been reported with HHS and acute renal failure in a patient with diabetes.^[22]C4

In children and adolescents, use biochemical criteria rather than diagnostic codes or presenting labels because HHS, DKA, and mixed hyperosmolar DKA may be misclassified.^{[2]B3b[11]B3b[19]C4} Pediatric cohorts show that HHS is uncommon but associated with substantial risk, while mixed presentations are more frequent than isolated HHS.^{[2]B3b[11]B3b} Risk assessment should include renal dysfunction, hemodynamic instability, neurologic impairment, and comorbidity, because these features influence the need for intensive monitoring.^{[4]A1c[11]B3b}

Practical conclusion

There is no diagnostic role for routine paired hormones, provocative endocrine testing, or localization studies in HHS. Confirm glucose ≥600 mg/dL, effective osmolality >300 mOsm/kg or total osmolality >320 mOsm/kg, and the absence or degree of ketoacidosis; then investigate sodium and water balance, neurologic complications, precipitating disease, and medication-related causes.^{[4]A1c[10]B3b[17]B3a[18]B3a[25]D5}

Diagnostic severity framework

Hyperglycemic hyperosmolar state (HHS) is a medical emergency characterized by profound hyperglycemia, increased plasma osmolality, and dehydration, usually with absent or limited ketoacidosis. Adult diagnostic frameworks differ internationally: United States-based criteria emphasize total serum osmolality, whereas UK guidance uses separate HHS criteria and places greater emphasis on the clinical and biochemical picture rather than a single universal definition. ^[28]D5 This variation means that HHS severity should not be assigned from glucose alone; serum sodium, measured or calculated osmolality, mental status, renal function, acid–base status, and the extent of fluid and electrolyte depletion should be assessed together. ^{[8]D5[28]D5[58]D}

A practical biochemical definition of severe HHS is plasma glucose ≥600 mg/dL (≥33.3 mmol/L) with effective osmolality ≥320 mOsm/kg, usually accompanied by marked dehydration and minimal ketonemia or acidosis. ^[28]D5[8]D5 Effective osmolality is clinically important because it better reflects the osmotic influence of sodium and glucose on brain water movement; total osmolality includes urea and may therefore differ from the effective value. ^[28]D5 Mental-status change becomes more likely as effective osmolality rises, and altered consciousness should be treated as a marker of severe disease rather than as a prerequisite for diagnosis. ^[1]D5[8]D5

HHS and diabetic ketoacidosis (DKA) are not mutually exclusive. A mixed DKA–HHS presentation should be considered when substantial ketonemia, metabolic acidosis, or a low pH accompanies marked hyperosmolality and hyperglycemia. ^{[2]B3b[28]D5[53]} In a retrospective Chinese cohort of 158 adults with type 2 diabetes and hyperglycemic emergencies, isolated DKA, isolated HHS, and combined DKA–HHS were all represented, supporting classification by the dominant biochemical phenotype rather than by diabetes type alone. ^[53]

Clinical staging

A useful clinical staging approach is based on neurological status and systemic complications. Stage 1 represents hyperosmolar hyperglycemia with preserved orientation and no major organ failure; stage 2 includes lethargy, confusion, focal neurological symptoms, hypotension, acute kidney injury, or clinically important electrolyte abnormalities; and stage 3 includes stupor or coma, shock, severe hypoxemia, seizures, cerebral edema, or multiorgan dysfunction. These stages are pragmatic risk categories rather than universally validated grades, because formal HHS severity scales and prospective outcome studies remain limited. ^{[1]D5[28]D5[41]D5}

Neurological findings can be prominent and may mimic acute stroke. In a systematic review of 18 reported non-epileptic cases of nonketotic HHS, hemianopia was the most frequent presentation, occurring in 73%, while partial or total anterior-circulation syndromes occurred in 26%. Patients with anterior-circulation-type symptoms were older than those with other stroke-like presentations, with mean ages of approximately 69.5 versus 52.2 years. ^[16]B3a Focal deficits therefore warrant urgent neurological assessment and appropriate brain imaging; they should not be attributed to hyperosmolarity without excluding ischemic stroke, seizure-related deficits, infection, or other structural disease. ^[1]D5[16]B3a

Risk stratification

The strongest immediate risk markers are extreme hyperosmolality, worsening neurological impairment, hypotension or shock, severe dehydration, acute kidney injury, major sodium or potassium abnormalities, significant acidosis or ketonemia, and serious precipitating illness. ^{[8]D5[28]D5[41]D5[58]D} HHS causes substantial losses of free water, sodium, and potassium through osmotic diuresis; the magnitude of depletion depends on the presenting glucose and sodium concentrations, the composition of urinary losses, and the patient’s baseline body-water stores. ^[58]D Measured serum sodium may rise during treatment as glucose falls and water shifts back intracellularly, so sodium trends must be interpreted with the glucose trajectory and overall fluid balance. ^[58]D

Older adults and people with chronic comorbidity may have particularly high mortality risk because HHS frequently occurs with infection, cardiovascular disease, renal dysfunction, or other acute illness. ^[41]D5[8]D5 In type 2 diabetes, emphysematous pyelonephritis and other severe urinary infections are clinically relevant potential complications or precipitants; in a prospective study of 200 patients with type 2 diabetes and upper urinary tract infection, emphysematous pyelonephritis occurred in 10% and was associated with substantial morbidity. ^[61]

Pediatric HHS is uncommon but high risk. In one pediatric cohort of 411 hyperglycemic emergencies, only 3 cases met criteria for isolated HHS, whereas 54 had mixed DKA–hyperosmolar presentations, indicating that overlap is more frequent than isolated HHS in hospitalized children. ^[2]B3b In a larger pediatric series of 4,565 admissions, isolated HHS accounted for 31 (0.7%) admissions and hyperosmolar DKA for 250 (5.4%); death or intensive-care-unit stay exceeding 48 hours was used as the adverse-outcome endpoint. ^[11]B3b Pediatric risk assessment should therefore incorporate age, altered mental status, degree of hyperosmolality, circulatory compromise, renal impairment, and whether DKA and HHS coexist. ^{[2]B3b[11]B3b}

COVID-19, obesity, and type 2 diabetes may further increase clinical complexity in adolescents, although evidence is largely case-based. ^[26]C4[3]D5 Persistent or disproportionately severe hypernatremia should prompt reassessment for ongoing free-water loss, renal or urinary pathology, and treatment-related factors; a case report described refractory hypernatremia despite glucose stabilization in a patient with partial urinary tract obstruction. ^[27]C4

Building upon the risk stratification and severity staging previously established, acute management of Hyperglycemic Hyperosmolar State (HHS) requires a time-critical, coordinated approach focused on aggressive volume expansion, gradual electrolyte correction, and controlled glycemic reduction. The ADA 2024 consensus report emphasizes that HHS carries a higher mortality risk than diabetic ketoacidosis (DKA) and requires more cautious fluid and insulin titration to avoid rapid osmotic shifts ^{[4]A1c[24]A1c}.

Step 1: Initial Assessment and Disposition

Clinicians must immediately determine the level of care based on the severity of hyperosmolality and comorbid stability.

• ICU Admission Criteria: Indicated for patients with an effective serum osmolarity > 320 mOsm/L, altered mental status, hemodynamic instability, or concurrent severe DKA ^{[4]A1c[10]B3b}.
• Diagnostic Refinement: While traditional criteria require a total serum osmolarity > 320 mOsm/L, an effective serum osmolarity > 300 mOsm/L is a more sensitive diagnostic threshold for identifying clinically significant HHS ^[10]B3b.
• Corrected Sodium: Management must be guided by sodium levels corrected for hyperglycemia; hypernatremia based on corrected sodium is present in 95.4% of HHS cases, reflecting the true free water deficit ^[10]B3b.

Step 2: Fluid Resuscitation

Fluid replacement is the most critical initial intervention to restore circulatory volume and improve end-organ perfusion.

1. Initial Bolus: Administer 0.9% sodium chloride (normal saline) at 15-20 mL/kg/h or 1-1.5 L during the first hour to stabilize blood pressure ^[4]A1c[32]D5.
2. Maintenance Phase: Subsequent fluid choice depends on the corrected serum sodium. If corrected sodium is normal or high, switch to 0.45% sodium chloride; if low, continue 0.9% sodium chloride at 250-500 mL/h ^[4]A1c.
3. Glucose Integration: When serum glucose reaches 300 mg/dL, transition to 5% dextrose with 0.45% sodium chloride to prevent hypoglycemia and allow continued insulin administration for osmolality correction ^[4]A1c.

Step 3: Potassium and Electrolyte Management

Insulin therapy will shift potassium intracellularly, risking fatal arrhythmias if not pre-emptively managed.

• Potassium Thresholds:
• If K+ < 3.3 mEq/L: Hold insulin; administer 20-30 mEq/h until K+ > 3.3 mEq/L ^[4]A1c.
• If K+ 3.3-5.2 mEq/L: Add 20-30 mEq of potassium to each liter of IV fluid to maintain serum levels between 4.0-5.0 mEq/L ^[4]A1c.
• If K+ > 5.2 mEq/L: Do not supplement; check levels every 2 hours ^[4]A1c.

Step 4: Insulin Therapy

Insulin should only be initiated after fluid resuscitation is underway and potassium is ≥ 3.3 mEq/L.

1. Regimen: Administer a continuous regular insulin infusion at 0.1 unit/kg/h, or a 0.1 unit/kg bolus followed by 0.1 unit/kg/h ^[4]A1c[5]D5.
2. Target Reduction: Aim for a glucose decrease of 50-70 mg/dL/h. If glucose does not fall by at least 50 mg/dL in the first hour, check fluid status; if adequate, increase insulin dose by hourly increments ^[4]A1c.
3. Subcutaneous Alternative: In mild to moderate cases where IV access or ICU resources are limited, subcutaneous rapid-acting insulin analogs may be considered, though IV remains the standard for severe HHS ^[4]A1c.

Step 5: Monitoring and Resolution

• Frequency: Monitor electrolytes, glucose, and venous pH every 2-4 hours; monitor vital signs and fluid balance hourly ^[4]A1c.
• Resolution Criteria: HHS is considered resolved when effective osmolality is < 310 mOsm/L, blood glucose is ≤ 250-300 mg/dL, and the patient has regained baseline mental status ^{[4]A1c[24]A1c}.

Controversies and Guideline Disagreement

Drug / Modality Comparison Table

What NOT to Do

• Do NOT initiate insulin if potassium is < 3.3 mEq/L, as this may precipitate cardiac arrest ^[4]A1c.
• Do NOT use bicarbonate therapy routinely; HHS patients typically do not have the severe acidemia seen in DKA, and bicarbonate may worsen hypokalemia ^[4]A1c[5]D5.
• Do NOT drop blood glucose faster than 70-100 mg/dL/h once the initial decline occurs, to minimize the risk of cerebral edema ^[4]A1c.

Pearl: Prioritize volume resuscitation over insulin; in HHS, the corrected sodium and effective osmolarity (target > 300 mOsm/L) are more accurate guides for fluid therapy than measured values ^{[10]B3b[24]A1c}.

Purpose and evidence boundaries

Long-term management after hyperglycemic hyperosmolar state (HHS) should be treated as a transition from emergency stabilization to durable diabetes care: identify the underlying diabetes phenotype, establish a sustainable glucose-lowering regimen, prevent recurrence, and address precipitating illness or treatment-related risks. The supplied references provide stronger evidence for recurrence risk, precipitating factors, comorbidity, and transition-of-care needs than for a single post-HHS biochemical target. Accordingly, individualized targets should be documented rather than inferred from the acute HHS episode. ^{[30]A1c[38]B3b[52]}

Replacement: restore sustainable diabetes treatment

After resolution of HHS, the treatment plan should replace the insulin deficiency or treatment gap that contributed to severe hyperglycemia. The regimen should be selected according to diabetes type, residual endogenous insulin secretion, renal function, nutritional status, affordability, health literacy, and the patient’s ability to monitor glucose and administer therapy. These factors are clinically important because hyperglycemic crises occur across both type 1 and type 2 diabetes and are associated with sociodemographic, clinical, and treatment-related characteristics. ^[38]B3b

Patients with type 1 diabetes require ongoing insulin replacement; patients with type 2 diabetes may require insulin temporarily or long term, depending on glycemic control and insulin secretory reserve. The pediatric consensus guideline identifies intravenous insulin as the treatment of choice during DKA and recognizes subcutaneous insulin as an option when intensive-care resources are limited, but it does not establish a universal long-term post-HHS regimen. ^[30]A1c Pediatric patients may have mixed DKA-HHS presentations, and diagnostic misclassification is reported; therefore, discharge therapy should be based on the complete biochemical and clinical phenotype rather than the admission label alone. ^[2]B3b[19]C4

Renal disease requires special caution. Adults with diabetes and end-stage kidney disease experience hyperglycemic crises and require treatment decisions that account for renal replacement therapy, altered fluid handling, and hypoglycemia risk. ^[13]B2b Long-term insulin and other glucose-lowering therapies should therefore be reassessed when kidney function changes, dialysis begins, or oral intake becomes unreliable. ^[13]B2b

Suppression: prevent recurrent hyperglycemia and triggers

Prevention should include a written sick-day plan, medication reconciliation, access to glucose monitoring and supplies, education on hydration and early clinical contact, and review of missed doses or barriers to treatment. Area-level socioeconomic deprivation is associated with emergency visits or hospitalization for hypoglycemic and hyperglycemic crises, supporting proactive assessment of transportation, medication affordability, food security, housing, and continuity of care. ^[52] Treatment-related and sociodemographic factors are also associated with hyperglycemic crises in adults with type 1 or type 2 diabetes. ^[38]B3b

Medication review is essential. Antipsychotic exposure has been associated in the clinical literature with DKA and HHS, and the available systematic review specifically evaluates both first- and second-generation antipsychotics. When clinically feasible, clinicians should review temporal relationships between antipsychotic treatment and dysglycemia, coordinate with psychiatry, and intensify glucose monitoring after initiation or dose changes rather than abruptly discontinuing effective psychiatric treatment. ^[18]B3a

SGLT2 inhibitors require particular caution in patients with unexplained persistent hypernatremia, polyuria, or disproportionate urinary dilution after HHS. A case report describes delayed recognition of central diabetes insipidus during dapagliflozin therapy because the drug obscured interpretation of urine concentration; stopping dapagliflozin permitted diagnostic confirmation. ^[21]C4 Persistent hypernatremia despite glucose improvement should prompt reassessment for ongoing water loss, urinary tract obstruction, or diabetes insipidus rather than assuming that HHS alone explains the abnormality. ^[21]C4[27]C4

Definitive: treat the cause and complications

HHS may be precipitated or complicated by serious infection, stroke-like neurologic syndromes, seizures, medication exposure, or major social and treatment barriers. Nonketotic HHS has been associated with acute stroke-like deficits, particularly hemianopia and anterior-circulation-like presentations, while seizures and characteristic magnetic-resonance abnormalities have also been reported. Persistent or recurrent neurologic symptoms require neurologic evaluation rather than attribution solely to glucose disturbance. ^{[16]B3a[17]B3a}

Infection surveillance should be individualized. Reported HHS-associated infections include rhino-orbital mucormycosis and emphysematous pyelonephritis, both requiring disease-specific therapy in addition to glucose management; reported treatment has included surgical debridement and antifungal therapy for mucormycosis, and antibiotics with urinary drainage or surgery for emphysematous pyelonephritis. ^[67]C[22]C4 These are not routine treatments for HHS, but they illustrate why an occult infectious precipitant must be definitively diagnosed and treated.

Fluid and electrolyte abnormalities may persist after plasma glucose improves. Hyperglycemic emergencies produce substantial losses of body water, sodium, and potassium, and the magnitude varies with presenting glucose, serum sodium, urinary losses, and body water. ^[58]D Consequently, post-discharge monitoring should include reassessment of volume status, sodium, potassium, renal function, and ongoing polyuria when clinically indicated. Evidence regarding the optimal rate of glucose reduction and cerebral-edema risk remains limited in adults; a retrospective study evaluated different correction rates but does not establish a definitive long-term target. ^[56]C

Follow-up and targets

A post-HHS visit should confirm the diabetes classification, review glucose records and treatment adherence, reconcile medications, assess renal function and electrolytes, screen for precipitating illness, and address social barriers. The available references do not provide a validated universal HbA1c, glucose, osmolality, or sodium target specifically for long-term HHS survivors; targets should therefore follow the patient’s diabetes phenotype and comorbidity profile, with avoidance of both recurrent severe hyperglycemia and treatment-related hypoglycemia. ^{[13]B2b[30]A1c[38]B3b[52]}

From DKA-centered protocols to recognition of HHS

Management of hyperglycemic hyperosmolar state (HHS) has evolved from treatment within broader diabetic-ketoacidosis (DKA) protocols toward recognition that profound hyperosmolality, dehydration, electrolyte disturbance, and neurologic dysfunction require individualized management. The supplied pediatric consensus guideline describes comprehensive guidance for both DKA and HHS, while emphasizing that the evidence and practical experience have historically been strongest for intravenous (IV) insulin in DKA. ^[30]A1c HHS may occur in children and adolescents with type 2 diabetes, although it remains uncommon in pediatrics; in a registry of 503 youth with newly diagnosed type 2 diabetes, 2% presented with HHS and 11% with DKA. ^[37]B2b

A pediatric case illustrates why treatment cannot rely on glucose concentration alone. A 15-year-old with HHS had glucose 90.9 mmol/L, measured serum osmolality 454 mOsm/kg, corrected sodium 165 mEq/L, pH 6.97, bicarbonate 5 mEq/L, and potassium 8.4 mEq/L, demonstrating a mixed HHS–DKA presentation with severe metabolic and electrolyte abnormalities. ^[42]C4 This experience helped reinforce the need to assess acid–base status, corrected sodium, osmolality, potassium, hemodynamics, and mental status rather than treating hyperglycemia in isolation. ^[42]C4

Fluid resuscitation and insulin-based treatment

The modern treatment sequence is centered on restoration of effective circulating volume, careful correction of water and electrolyte deficits, and insulin to reverse hyperglycemia. A recent case involving HHS with refractory hypernatremia reported use of standard care, including insulin therapy and fluid resuscitation; serum glucose stabilized, but severe hypernatremia persisted in the setting of partial urinary tract obstruction, bilateral hydronephrosis, ureteral dilation, benign prostatic hyperplasia, and bladder calculi. ^[27]C4 The report underscores that persistent hypernatremia after improvement in glucose may reflect ongoing urinary water loss or an uncorrected obstructive process rather than inadequate insulin alone. ^[27]C4

IV insulin remains the treatment of choice for DKA in the ISPAD consensus guideline, which also addresses HHS management in young people. ^[30]A1c However, conventional IV insulin frequently requires intensive-care admission under hospital policy, creating logistical problems during the COVID-19 pandemic and in resource-limited settings. ^[30]A1c The guideline therefore examined subcutaneous insulin as an alternative when ICU capacity is constrained or ICU admission is inappropriate because of infection-transmission concerns, while retaining IV insulin as the preferred approach when resources and clinical circumstances permit. ^[30]A1c This represents an important evolution from a single-location, ICU-dependent model toward risk-adapted delivery of insulin therapy. ^[30]A1c

Expansion of treatment to precipitating factors and special populations

Contemporary care increasingly treats the precipitating illness or circumstance alongside the hyperglycemic crisis. In adults with type 2 diabetes, upper urinary tract infection may be complicated by emphysematous pyelonephritis, a severe infection associated with substantial morbidity and poor prognosis; a prospective study of 200 patients with type 2 diabetes and upper urinary tract infection identified pyelonephritis in 90% and emphysematous pyelonephritis in 10%. ^[61] These data support active investigation for infection when HHS occurs, although the study did not specifically test an HHS treatment protocol. ^[61]

The range of recognized precipitants has also broadened. A four-case report linked cocaine use to DKA or HHS through mechanisms including missed insulin doses, altered mental status, and concurrent serious illness such as pneumonia and sepsis. ^[68]C Immune checkpoint inhibitor–associated diabetes is another emerging context: a literature review and case report described acute immune checkpoint inhibitor–induced type 1 diabetes that can progress rapidly to DKA or HHS, including a case associated with cadonilimab. ^[20]D5 These reports support medication review, assessment of adherence, screening for infection, and consideration of drug-related diabetes when selecting treatment and prevention strategies. ^[20]D5[68]C

Prevention, recurrence, and population-based care

Treatment has consequently expanded beyond acute bedside correction to prevention of repeat crises. A retrospective case-control study of 367 patients evaluated predictors of recurrent DKA or HHS admission, reflecting the shift toward identifying modifiable readmission risks after stabilization. ^[57] A large U.S. claims-based cohort study similarly evaluated sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises among adults with type 1 or type 2 diabetes from 2014–2020. ^[38]B3b In adults with diabetes and end-stage kidney disease, a nationwide registry study assessed annual emergency-department visits and hospitalizations for DKA or HHS from 2013–2017 while accounting for age, sex, race/ethnicity, dialysis modality, comorbidities, treatment regimen, and region. ^[13]B2b

Prevention also includes culturally and behaviorally tailored education. A multicenter Pakistani study implemented Ramadan-specific counseling and educational materials for people with diabetes before fasting, with follow-up after Ramadan; glucose monitoring was reported by all participants with type 1 diabetes and by 71.43% of those with type 2 diabetes when hypoglycemic symptoms occurred. ^[36]B2b Although this study focused on Ramadan-related diabetes management rather than HHS treatment, it illustrates the evolution toward anticipatory education and individualized risk reduction. ^[36]B2b The supplied adult bacterial-meningitis study examined sex-based epidemiology and therapeutic outcomes, but it did not evaluate HHS treatment; its relevance to this section is limited to the broader principle that severe infection remains an important competing diagnostic and management consideration in acutely ill adults. ^[39]B3b

Genetic predispositions and syndromic associations significantly influence the risk and severity of Hyperglycemic Hyperosmolar State (HHS), particularly when metabolic stressors perturb multiple endocrine axes. While HHS is classically associated with type 2 diabetes, it increasingly occurs in pediatric populations with complex genetic backgrounds or as a complication of pharmacotherapy for other endocrine disorders ^[11]B3b, ^[6]C4.

Genetic and Syndromic Associations

Inherited syndromes that affect neurodevelopment or metabolic regulation can predispose patients to extreme hyperglycemic crises. Cases of HHS have been documented in children with Joubert syndrome, where patients may present with extreme glucose elevations (e.g., 115 mmol/L) and severe dehydration ^[43]C4. The intersection of obesity and type 2 diabetes in adolescents, often linked to polygenic or syndromic factors, represents a high-risk group for severe metabolic decompensation, especially when triggered by acute infections like COVID-19 ^[26]C4.

Pharmacogenetic Risks and Co-Axis Effects

Therapeutic interventions for other endocrine axes can inadvertently precipitate HHS. A critical example involves the use of diazoxide for congenital hyperinsulinism. Novel variants in the HNF1A gene can cause extreme hypersensitivity to diazoxide , where even conventional doses (5 mg/kg/day) or low doses (3 mg/kg/day) may trigger rapid transitions from hypoglycemia to severe hyperglycemia ^[6]C4. Clinicians must monitor for HHS when initiating diazoxide in patients with HNF1A mutations, as the resulting metabolic shift can be mutation-specific and require doses as low as 0.7 mg/kg/day to maintain euglycemia ^[6]C4.

Neurological and Systemic Axis Perturbations

The profound hyperosmolality of HHS frequently manifests as acute neurological dysfunction, which may mimic primary cerebrovascular events. These "stroke-like" deficits are often metabolic rather than structural in origin ^[16]B3a.

• Neurological Findings: Hemianopia is the most common presentation (73%), followed by anterior circulation syndromes (26%) ^[16]B3a.
• Imaging Signatures: T2-FLAIR MRI sequences frequently show subcortical hypointensities, while cortical DWI hyperintensities occur in 64% of cases ^[16]B3a.
• Resolution: Symptoms typically resolve within 6 days (IQR 3-10) following aggressive glucose normalization ^[16]B3a.

Risk Factors for Adverse Outcomes

In pediatric and adolescent populations, the presence of type 2 diabetes is a primary driver of morbidity. A multivariable model identified maximum serum glucose, initial pH, and a diagnosis of type 2 diabetes as the strongest predictors of adverse outcomes (AUC 0.948) ^[11]B3b.

Pearl: In patients with HNF1A-related hyperinsulinism, diazoxide can precipitate HHS at standard doses; initiate therapy at low doses and monitor for rapid glycemic escalation ^[6]C4.

Chronic metabolic derangements following an episode of hyperglycemic hyperosmolar state (HHS) necessitate rigorous surveillance for both acute multi-organ failure and long-term vascular or endocrine sequelae. While the immediate focus remains on fluid resuscitation and insulin therapy, the transition to long-term management must address the high risk of recurrence and the systemic damage incurred during the hyperosmolar crisis.

Acute and Autonomic Complications

The extreme hyperosmolality and dehydration characteristic of HHS predispose patients to severe multi-organ dysfunction. In pediatric and adolescent populations, early recognition of hyperosmolality is critical to prevent complications such as arrhythmia, rhabdomyolysis , and acute kidney injury (AKI) ^[19]C4. Severe cases may require renal replacement therapy to manage AKI ^[19]C4. Furthermore, the metabolic stress of HHS can trigger or occur concurrently with acute pancreatitis, which complicates the clinical course and increases the risk of subsequent glycemic instability ^[9]B2b[19]C4.

Respiratory and Hospital-Acquired Monitoring

Patients with HHS often require intensive care monitoring due to the risk of respiratory failure or altered consciousness. While intravenous insulin remains the standard of choice, subcutaneous insulin may be considered in resource-limited settings for uncomplicated cases to prioritize ICU capacity ^[30]A1c. Monitoring for hospital-acquired complications is essential, as the median length of stay for acute diabetes-related hospitalizations is approximately 3 to 4 days ^[15]B2b.

Long-term Sequelae and Mortality Risk

Survivors of HHS face significantly elevated long-term mortality and morbidity. Patients with comorbid conditions like chronic pancreatitis have a 5.0-fold higher risk for HHS and a 2.43-fold higher risk for death compared to those without pancreatic inflammation ^[9]B2b. Cumulative survival rates in these high-risk populations decline from 98.4% at 1 year to 78.7% at 10 years ^[9]B2b.

Preventive Strategies and Technology

The implementation of intermittently scanned continuous glucose monitoring ( isCGM ) has demonstrated significant utility in reducing long-term sequelae. In insulin-treated type 2 diabetes, isCGM use is associated with a reduction in diabetes-related hospitalization rates from 74.6 to 27.5 per 10,000 person-years ^[15]B2b. This technology also correlates with a decrease in mean HbA1c from 8.09% to 7.65%, potentially mitigating the risk of future hyperglycemic emergencies ^[15]B2b.

Pearl: Early recognition of hyperosmolality is the primary determinant of outcome; inadequate fluid rehydration in the initial treatment phase is a major contributor to rhabdomyolysis and multi-organ failure ^[19]C4.

The clinical trajectory of HHS is characterized by a higher mortality rate than diabetic ketoacidosis, often due to the advanced age of patients and the severity of underlying precipitating illnesses ^[4]A1c. While inpatient admission rates for HHS increased significantly between 2009 and 2015 (APC 6.3%), the prognosis remains heavily dependent on the speed of metabolic correction and the management of concurrent complications ^[14]B2c.

Prognostic Determinants and Mortality

Mortality in HHS is frequently driven by the primary precipitating event, such as sepsis or myocardial infarction, rather than the metabolic derangement alone ^[4]A1c. In specific high-risk cohorts, such as patients with chronic pancreatitis, the 10-year cumulative survival rate is significantly lower at 78.7% compared to 93.6% in matched diabetic controls (HR 2.43) ^[9]B2b.

• Neurological Recovery: Stroke-like deficits, including hemianopia (73%) and anterior circulation syndromes (26%), typically resolve within 6 days (IQR 3-10) following glucose normalization ^[16]B3a.
• Fatalities in Drug-Induced Cases: In cases associated with atypical antipsychotics, fatalities have been documented, including those involving olanzapine ^[18]B3a.
• Renal Factors: Persistent hypernatremia (e.g., peaks of 162.3 mmol/L) may indicate secondary complications like urinary tract obstruction, which requires surgical resolution to normalize sodium levels ^[27]C4.

Natural History and Recurrence

Without aggressive intervention, the natural history of HHS progresses toward profound dehydration, coma, and death ^[1]D5. The condition primarily affects middle-aged adults (47.5% aged 45-64) and those with type 2 diabetes (88.1%) ^[14]B2c. Emerging triggers, such as immune checkpoint inhibitors (e.g., cadonilimab ), can cause rapid progression from new-onset diabetes to HHS, necessitating lifelong insulin therapy ^[20]D5.

Prevention and Screening

Prevention strategies focus on early recognition of rising glucose levels and the management of modifiable risk factors ^[4]A1c. The 2024 ADA consensus report emphasizes that approximately 40% of hyperglycemic crises occur in lower-income populations, suggesting that socioeconomic barriers to medication adherence are a primary target for prevention ^{[14]B2c[24]A1c}.

• Patient Education: Instruction on "sick day rules," including frequent glucose monitoring and maintaining hydration during acute illness ^[4]A1c.
• Medication Vigilance: Routine metabolic monitoring for patients prescribed second-generation antipsychotics, particularly olanzapine and clozapine , which are associated with extreme hyperglycemia (mean glucose 1252.8 mg/dL in HHS cases) ^[18]B3a.
• Clinical Monitoring: Early investigation of urological symptoms in elderly males to prevent obstructive-induced electrolyte crises ^[27]C4.

Pearl: Neurological deficits in HHS often mimic acute stroke but typically resolve within 3 to 10 days of metabolic correction, provided subcortical hypointensities on T2-FLAIR MRI are identified early ^[16]B3a.

Management of hyperosmolar emergencies must be tailored to the physiological shifts of specific patient groups, as the standard protocols for fluid and insulin titration may require adjustment to account for age-related frailty or developmental risks. While the core principles of aggressive rehydration and electrolyte correction remain, the risk profile for complications like cerebral edema or multi-organ failure varies significantly across the lifespan ^[19]C4[25]D5.

Pediatrics and Adolescents

Pediatric cases are increasingly linked to the rise in adolescent obesity and type 2 diabetes, with an incidence of 2% reported in a United States multicenter study ^[19]C4. Diagnosis is frequently complicated by a mixed clinical picture where features of hyperosmolality and ketoacidosis coexist, leading to initial misdiagnosis as diabetic ketoacidosis (DKA) in 5 out of 9 cases in one series ^[19]C4.

• Fluid Management: Early recognition of hyperosmolality is essential to initiate more vigorous fluid replacement than is standard for DKA ^[19]C4.
• Insulin Delivery: While intravenous infusion is the standard of care, subcutaneous insulin may be considered for uncomplicated mild to moderate DKA/HHS in resource-limited settings or during pandemic-related ICU constraints ^[30]A1c.
• Complications: Pediatric patients are at risk for severe sequelae including arrhythmia, acute kidney injury requiring renal replacement therapy, rhabdomyolysis , and acute pancreatitis ^[19]C4.

Elderly Patients

Elderly individuals represent the classic demographic for this condition, often presenting with type 2 diabetes and significant comorbidities ^[25]D5[46]D5. Management is complicated by age-related physiological changes, sarcopenia, and varying levels of cognitive or mobility impairment ^[46]D5.

• Diagnostic Considerations: Elderly males presenting with unexplained, refractory hypernatremia (e.g., serum sodium peaking at 162.3 mmol/L) should be evaluated for partial urinary tract obstruction, such as benign prostatic hyperplasia or bladder calculi, which can impair renal medullary concentrating ability ^[27]C4.
• Neurological Findings: "Diabetic striatopathy," characterized by dyskinesias and basal ganglia hyperintensities on neuroimaging, is most commonly reported in elderly females with hyperosmolar states ^[44]C4.
• Risk Profile: This population faces an elevated risk of cardiovascular disease, cancer, and mortality, necessitating a personalized strategy that balances aggressive crisis management with the risks of severe hypoglycemia ^[46]D5.

Perioperative and Acute Stress

Inpatient management during the perioperative period or acute illness (such as COVID-19 ) requires integration of evolving technologies like continuous glucose monitoring and computer-guided insulin dosing software to improve safety and glycemic control ^[45]D5. The choice of crystalloid, comparing 0.9% saline to buffered solutions like Lactated Ringer's or Hartmann's, remains a critical decision point for clinicians managing large-volume resuscitation in these high-stress states ^[32]D5.

Pearl: In pediatric patients, always calculate the effective osmolality early, as over half of cases may initially mask as simple DKA, leading to under-resuscitation ^[19]C4.